CO5650229A2 - Sales farmaceuticamente utiles de derivados de acido carboxilico - Google Patents
Sales farmaceuticamente utiles de derivados de acido carboxilicoInfo
- Publication number
- CO5650229A2 CO5650229A2 CO05130776A CO05130776A CO5650229A2 CO 5650229 A2 CO5650229 A2 CO 5650229A2 CO 05130776 A CO05130776 A CO 05130776A CO 05130776 A CO05130776 A CO 05130776A CO 5650229 A2 CO5650229 A2 CO 5650229A2
- Authority
- CO
- Colombia
- Prior art keywords
- salt
- acid derivatives
- pharmaceutically useful
- carboxyl acid
- oxoethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1.- Una sal de calcio o magnesio de ácido (2S)-2-etoxi-3-(4-{2-[hexil(2-feniletil)-amino]-2-oxoetoxi} fenil) propanoico.2.- Una sal de calcio de ácido (2S)-2-etoxi-3-( 4-{2-[hexil(2-feniletil)amino]-2-oxoetoxi}fenil)propanoico.3.- Una sal como se reivindica en cualquiera de las dos reivindicaciones 1 ó 2, que puede ser un solvato, un hidrato, un solvato/hidrato mixto, un ansolvato o un anhidrato.4.- Una sal como se reivindica en una cualquiera de las reivindicaciones 1-3 en forma cristalina o parcialmente cristalina.5.- Una sal como se reivindica en una cualquiera de las reivindicaciones 1-4, en la forma de una sal mixta junto con un ión contrario farmacéuticamente inactivo.6.- Una sal como se reivindica en una cualquiera de las reivindicaciones 2-4, en donde el ión contrario farmacéuticamente inactivo es [CaCl]+.7.- Una formulación farmacéutica que comprende un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 6 en mezcla con coadyuvantes, diluyentes y/o excipientes farmacéuticamente aceptables.8.- Un método de tratar o prevenir trastornos de lípidos (dislipidemia), asociados o no con resistencia a la insulina, que comprende la administración de un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 6 a un mamífero necesitado de él.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0314136.3A GB0314136D0 (en) | 2003-06-18 | 2003-06-18 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5650229A2 true CO5650229A2 (es) | 2006-06-30 |
Family
ID=27636795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05130776A CO5650229A2 (es) | 2003-06-18 | 2005-12-28 | Sales farmaceuticamente utiles de derivados de acido carboxilico |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20060194879A1 (es) |
| EP (1) | EP1638921A1 (es) |
| JP (1) | JP3836498B1 (es) |
| KR (1) | KR20060017646A (es) |
| CN (1) | CN1805922A (es) |
| AR (1) | AR044802A1 (es) |
| AU (1) | AU2004247611A1 (es) |
| BR (1) | BRPI0411455A (es) |
| CA (1) | CA2527608A1 (es) |
| CO (1) | CO5650229A2 (es) |
| GB (1) | GB0314136D0 (es) |
| IL (1) | IL172168A0 (es) |
| IS (1) | IS8232A (es) |
| MX (1) | MXPA05013713A (es) |
| NO (1) | NO20055923L (es) |
| RU (1) | RU2005138369A (es) |
| SA (1) | SA04250170B1 (es) |
| TW (1) | TW200503678A (es) |
| UY (1) | UY28371A1 (es) |
| WO (1) | WO2004110985A1 (es) |
| ZA (1) | ZA200510199B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0229931D0 (en) * | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| ATE386013T1 (de) | 2002-06-20 | 2008-03-15 | Astrazeneca Ab | Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz |
| WO2007004957A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | Novel crystalline form |
| AR055073A1 (es) * | 2005-07-11 | 2007-08-01 | Astrazeneca Ab | Agentes terapeuticos |
| FR2903985B1 (fr) | 2006-07-24 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2904316B1 (fr) | 2006-07-31 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. |
| PE20081463A1 (es) * | 2006-10-20 | 2008-10-18 | Janssen Pharmaceutica Nv | Formas salinas de compuestos de benzotienilo sustituido |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1167357A4 (en) * | 1999-04-06 | 2002-06-05 | Sankyo Co | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
-
2003
- 2003-06-18 GB GBGB0314136.3A patent/GB0314136D0/en not_active Ceased
-
2004
- 2004-06-09 TW TW093116599A patent/TW200503678A/zh unknown
- 2004-06-16 WO PCT/SE2004/000965 patent/WO2004110985A1/en active Application Filing
- 2004-06-16 RU RU2005138369/04A patent/RU2005138369A/ru not_active Application Discontinuation
- 2004-06-16 SA SA04250170A patent/SA04250170B1/ar unknown
- 2004-06-16 EP EP04736956A patent/EP1638921A1/en not_active Withdrawn
- 2004-06-16 AU AU2004247611A patent/AU2004247611A1/en not_active Abandoned
- 2004-06-16 CN CNA2004800168384A patent/CN1805922A/zh active Pending
- 2004-06-16 CA CA002527608A patent/CA2527608A1/en not_active Abandoned
- 2004-06-16 BR BRPI0411455-8A patent/BRPI0411455A/pt not_active IP Right Cessation
- 2004-06-16 KR KR1020057024066A patent/KR20060017646A/ko not_active Application Discontinuation
- 2004-06-16 JP JP2006517040A patent/JP3836498B1/ja not_active Expired - Fee Related
- 2004-06-16 US US10/560,127 patent/US20060194879A1/en not_active Abandoned
- 2004-06-16 MX MXPA05013713A patent/MXPA05013713A/es not_active Application Discontinuation
- 2004-06-17 AR ARP040102112A patent/AR044802A1/es not_active Application Discontinuation
- 2004-06-17 UY UY28371A patent/UY28371A1/es not_active Application Discontinuation
-
2005
- 2005-11-24 IL IL172168A patent/IL172168A0/en unknown
- 2005-12-13 NO NO20055923A patent/NO20055923L/no not_active Application Discontinuation
- 2005-12-14 ZA ZA200510199A patent/ZA200510199B/en unknown
- 2005-12-28 CO CO05130776A patent/CO5650229A2/es unknown
-
2006
- 2006-01-13 IS IS8232A patent/IS8232A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1638921A1 (en) | 2006-03-29 |
| WO2004110985A1 (en) | 2004-12-23 |
| RU2005138369A (ru) | 2007-07-27 |
| UY28371A1 (es) | 2005-01-31 |
| AR044802A1 (es) | 2005-10-05 |
| GB0314136D0 (en) | 2003-07-23 |
| US20060194879A1 (en) | 2006-08-31 |
| AU2004247611A1 (en) | 2004-12-23 |
| JP3836498B1 (ja) | 2006-10-25 |
| BRPI0411455A (pt) | 2006-07-18 |
| KR20060017646A (ko) | 2006-02-24 |
| ZA200510199B (en) | 2006-12-27 |
| NO20055923L (no) | 2006-01-06 |
| MXPA05013713A (es) | 2006-06-27 |
| JP2006527767A (ja) | 2006-12-07 |
| IS8232A (is) | 2006-01-13 |
| CA2527608A1 (en) | 2004-12-23 |
| CN1805922A (zh) | 2006-07-19 |
| IL172168A0 (en) | 2009-02-11 |
| SA04250170B1 (ar) | 2007-10-29 |
| TW200503678A (en) | 2005-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5650229A2 (es) | Sales farmaceuticamente utiles de derivados de acido carboxilico | |
| AU2019203820B2 (en) | Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution | |
| CO6300929A2 (es) | Composicion oral que contiene amino acidos y sal soluble de calcio | |
| US10517845B2 (en) | Compositions and methods for treating intestinal hyperpermeability | |
| AR094070A1 (es) | Haluro de zinc aminoacidos / trimetilglicina | |
| CN113893239A (zh) | 用于治疗肠渗透性过高的酪氨酸羟化酶抑制剂 | |
| UY27300A1 (es) | Nuevos derivados de quinolina | |
| JP6060168B2 (ja) | レバミピドと涙液保持作用を有する薬剤からなる前眼部疾患治療剤 | |
| BRPI0515931A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos | |
| ECSP056182A (es) | Derivados de carbostirilo y estabilizantes del estado de ánimo para tratar trastornos del mismo | |
| BRPI0916456B8 (pt) | compostos lipídicos, composições de suplemento alimentar, farmacêuticas e lipídicas, método para produção de compostos lipídicos e uso de compostos lipídicos | |
| FI962749A (fi) | Uusia heterosyklisiä yhdisteitä | |
| UY27646A1 (es) | Derivados de quinolina como antagonistas de npt | |
| PE20050822A1 (es) | Derivados de florfenicol con mejor solubilidad en agua | |
| JP2017536372A5 (es) | ||
| UY27462A1 (es) | Derivados de quinolina | |
| NO20050667L (no) | N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes | |
| US4656177A (en) | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | |
| US5807541A (en) | NSAID/fluoride periodontal compositions and methods | |
| BR0313278A (pt) | Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo e sua utilização, método para o tratamento e profilaxia de enfermidades e obesidade e utilização dos compostos | |
| JP2002114686A (ja) | 点眼剤組成物 | |
| EA200300614A1 (ru) | Кристаллические соли металл-глюкозамин сульфата и способы их приготовления | |
| CO5650240A2 (es) | Sal de sodio o potasio de acido (-)-2-{[2-(4-hidroxifenil)etil]tio}-3-[4-(2-{4-[(metilsulfonil)oxi]fenoxi}etil)fenil-propanoico y su uso en medicina | |
| BR0312712A (pt) | Aminoácido modificado para a inibição da agregação plaquetária | |
| JP2019094300A (ja) | 点眼剤組成物 |